Pin Wang

Prof. Pin Wang is a leading scientist in the field of immune engineering and targeted gene/drug delivery. He has published more than 70 papers in top-tier journals including Nature Biotechnology, P.N.A.S, Nano Letter, ACS Nano, Gene Therapy, Human Gene Therapy, Molecular Therapy, J.A.C.S, Pharmaceutical Research, Vaccine, Biomaterials, Molecular Pharmaceutic. He has 4 patents under approval by USPTO. The DC targeting lentiviral vector developed in his team has entered Phase I clinical trial NCT02122861.

Prof. Wang has long been engaged in translational research and is an entrepreneur dedicated to the industrialization of basic research. He has co-founded 3 biotech companies in the United States: Immune Design, EvoRx Technology, and Vali Nanomedical. Immune Design eventually entered IPO at NASDAQ and was acquired by Merck in 2018. Prof. Wang has also been involved in the foundation of Hrain Biotechnology as a scientific consultant, whose work demonstrated clinical excellence and received IND approval from the CFDA. His team has profound experience in next-generation cancer vaccines and CAR-T design, as well as high-performance viral product manufacturing.